Aenova, a leading pharmaceutical Contract Development & Manufacturing Organisation (CDMO), has announced a significant expansion of their Killorglin facility (Temmler Ireland Ltd.) enabling the company to develop innovative drug delivery systems in the future.
This programme represents an ambitious expansion programme for the development capabilities at the Killorglin site. It will place the Aenova site in Ireland at the centre of the company’s development capabilities in particle engineering, focusing on spray-dried amorphous solid dispersions and inhalation powders. This strategic investment aims to improving bioavailability of poorly soluble drugs, which constitute approximately 80 % of compounds in global research pipelines.
This project is supported by the Irish Government through IDA Ireland.
Minister for Enterprise Tourism & Enterprise Peter Burke TD said: “I warmly congratulate Aenova on this exciting expansion of its Killorglin facility, which not only strengthens Ireland’s position in advanced pharmaceutical development but also brings high-value employment to County Kerry. This investment is a strong vote of confidence in the South-West region’s skilled workforce, world-class research partnerships, and thriving life sciences ecosystem.”
The Government, through IDA Ireland, is proud to support Aenova’s growth, and this announcement is a further step in delivering on our ambition for balanced, sustainable economic growth across all parts of Ireland. I wish the Aenova team the very best for the future.”
Minister for Children, Disability and Equality Norma Foley said: “I welcome Aenova’s substantial investment in their pharmaceutical facility in Killorglin, which has led to the creation of 10 new jobs in research and development, pharmaceutical technology and analytics. This is a resounding endorsement of the talented workforce here and shows what an attractive location Kerry is for inward investment. I wish to congratulate Aenova and I look forward to working with the company into the future.”
Established in 1972 as Klinge Pharma, Aenova employs approximately 70 people directly at its Killorglin facility, along with many other downstream positions in their many service providers. In 2007, Temmler Pharma took over the Killorglin site and in 2012, Temmler Pharma was acquired by Aenova Group, a leading European CDMO company in the pharmaceutical and nutraceutical industries.
“As an end-to-end CDMO, Aenova supports its customers throughout the entire drug product lifecycle, from pre-formulation and development to commercial manufacturing. Bioavailability is crucial for new pharmaceutical active ingredients. Our new spray drying technology in Killorglin can help to address this issue and aid our customers bring their products to market faster”, says Florent Bordet, Chief Scientific Officer at Aenova.
The expansion of the Killorglin facility will create approximately 10 new roles in the areas of R&D, Pharmaceutical Technology and Analytics. To explore opportunities to join the team visit Killorglin.
“Aenova’s spray drying services for amorphous solid dispersions are located at our Killorglin site. Here, we offer laboratory- and pilot-scale equipment for developing formulations, using APIs (Active Pharmaceutical Ingredients) up to OEB 4 (>1 µg/m³). We have the capability to handle organic solvents, and we collaborate closely with scientific researchers at the universities of Cork and Limerick," says Aidan Spillane, managing director at the Aenova Killorglin site.
CEO of IDA Ireland, Michael Lohan said: “Since 1972 under the stewardship of Klinge, Temmler and now Aenova, this facility has continually fostered opportunities, investment, and employment in Killorglin. Supporting our client companies is central to IDA Ireland's Adapt Intelligently: A Strategy for Sustainable Growth and Innovation 2025-29. I wish to congratulate Aenova on this significant expansion and assure them of IDA Ireland’s continued support.”
This programme represents an ambitious expansion programme for the development capabilities at the Killorglin site. It will place the Aenova site in Ireland at the centre of the company’s development capabilities in particle engineering, focusing on spray-dried amorphous solid dispersions and inhalation powders. This strategic investment aims to improving bioavailability of poorly soluble drugs, which constitute approximately 80 % of compounds in global research pipelines.
This project is supported by the Irish Government through IDA Ireland.
Minister for Enterprise Tourism & Enterprise Peter Burke TD said: “I warmly congratulate Aenova on this exciting expansion of its Killorglin facility, which not only strengthens Ireland’s position in advanced pharmaceutical development but also brings high-value employment to County Kerry. This investment is a strong vote of confidence in the South-West region’s skilled workforce, world-class research partnerships, and thriving life sciences ecosystem.”
The Government, through IDA Ireland, is proud to support Aenova’s growth, and this announcement is a further step in delivering on our ambition for balanced, sustainable economic growth across all parts of Ireland. I wish the Aenova team the very best for the future.”
Minister for Children, Disability and Equality Norma Foley said: “I welcome Aenova’s substantial investment in their pharmaceutical facility in Killorglin, which has led to the creation of 10 new jobs in research and development, pharmaceutical technology and analytics. This is a resounding endorsement of the talented workforce here and shows what an attractive location Kerry is for inward investment. I wish to congratulate Aenova and I look forward to working with the company into the future.”
Established in 1972 as Klinge Pharma, Aenova employs approximately 70 people directly at its Killorglin facility, along with many other downstream positions in their many service providers. In 2007, Temmler Pharma took over the Killorglin site and in 2012, Temmler Pharma was acquired by Aenova Group, a leading European CDMO company in the pharmaceutical and nutraceutical industries.
“As an end-to-end CDMO, Aenova supports its customers throughout the entire drug product lifecycle, from pre-formulation and development to commercial manufacturing. Bioavailability is crucial for new pharmaceutical active ingredients. Our new spray drying technology in Killorglin can help to address this issue and aid our customers bring their products to market faster”, says Florent Bordet, Chief Scientific Officer at Aenova.
The expansion of the Killorglin facility will create approximately 10 new roles in the areas of R&D, Pharmaceutical Technology and Analytics. To explore opportunities to join the team visit Killorglin.
“Aenova’s spray drying services for amorphous solid dispersions are located at our Killorglin site. Here, we offer laboratory- and pilot-scale equipment for developing formulations, using APIs (Active Pharmaceutical Ingredients) up to OEB 4 (>1 µg/m³). We have the capability to handle organic solvents, and we collaborate closely with scientific researchers at the universities of Cork and Limerick," says Aidan Spillane, managing director at the Aenova Killorglin site.
CEO of IDA Ireland, Michael Lohan said: “Since 1972 under the stewardship of Klinge, Temmler and now Aenova, this facility has continually fostered opportunities, investment, and employment in Killorglin. Supporting our client companies is central to IDA Ireland's Adapt Intelligently: A Strategy for Sustainable Growth and Innovation 2025-29. I wish to congratulate Aenova on this significant expansion and assure them of IDA Ireland’s continued support.”
